Madeline Hess
Associate
Madeline Hess is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. She focuses on patent prosecution and intellectual property counseling.
During law school, Madeline participated in the school’s Startup Ventures Clinic, counseling local entrepreneurs on intellectual property matters, entity formation, and corporate governance.
Experience
Madeline Hess is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. She focuses on patent prosecution and intellectual property counseling.
During law school, Madeline participated in the school’s Startup Ventures Clinic, counseling local entrepreneurs on intellectual property matters, entity formation, and corporate governance.
Education
- J.D., Duke University School of Law, 2021
- B.S., Chemical and Biochemical Engineering, University of Iowa, 2018
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., Duke University School of Law, 2021
- B.S., Chemical and Biochemical Engineering, University of Iowa, 2018
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Diagnostics and Medical Devices
- Biomedical devices
- Biomedical engineering
- Biosensors
- Medical devices
- miRNA detection
- Wearable analyte sensors
Chemistry and Material Science
- Chemistry
- Green chemistry
- Materials chemistry
- Photovoltaic materials
- Polymers
- Process chemistry
Engineering and Technology
- Materials science
- Mechanical engineering
- Microfluidics
Genomics and Data Analysis
- Next-generation sequencing
- Sequencing
- Single-cell sequencing
Technical Fluency
Diagnostics and Medical Devices
- Biomedical devices
- Biomedical engineering
- Biosensors
- Medical devices
- miRNA detection
- Wearable analyte sensors
Chemistry and Material Science
- Chemistry
- Green chemistry
- Materials chemistry
- Photovoltaic materials
- Polymers
- Process chemistry
Engineering and Technology
- Materials science
- Mechanical engineering
- Microfluidics
Genomics and Data Analysis
- Next-generation sequencing
- Sequencing
- Single-cell sequencing
Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Galvanize Therapeutics on $100 Million Series C Financing
On September 3, 2025, Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, announced that it has raised $100 million in an oversubscribed Series C financing. The round was led by Sofinnova Partners, with participation from a global syndicate of top-tier investors including Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, and Longaeva. Existing investors Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, Intuitive Surgical, and Apple Tree Partners (ATP), the company's founding investor, also participated in the round. Wilson Sonsini Goodrich & Rosati advised Galvanize on the transaction. The proceeds from the financing will be used to expand the company's commercial footprint and advance its clinical and development activities related to Aliya® PEF in solid tumors and RheOx® therapy for chronic bronchitis.
The Wilson Sonsini team that advised Galvanize on the transaction included:
The Wilson Sonsini team that advised Galvanize on the transaction included:
Learn More
Client Highlights
Firm Advises Matterworks on IP and Patent Matters Related to Series A Financing
On June 3, 2025, Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, announced a new Series A financing. The round was led by Lewis & Clark Partners and OMX Ventures and joined by Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia, among others. Matterworks will use the Series A proceeds to grow its model as a service (MaaS) business and expand its machine learning and scientific operations. For example, Matterworks' Large Spectral Models (LSMs) productize self-supervised machine intelligence for direct machine interpretation of molecular-omic data. The company’s PyxisTMproduct, released in 2024, is the first generative AI for complete untargeted molecular annotation, unlocking new data modalities for understanding and predicting complex biological outcomes.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.